Improving outcomes for patients with acute myeloid leukemia in first relapse: A single center experience

摘要: The outcome of patients with relapsed acute myeloid leukemia (AML) remains unsatisfactory, few available effective therapies. Increased understanding the biology disease has led to identification novel therapeutic agents, several which have been evaluated in recently conducted clinical trials. We sought determine whether introduction these agents as well modern supportive care measures already translated better outcomes. examined outcomes 1,056 AML first relapse treated between January 1993 and December 2013 at our institution. As previously reported, independent prognostic factors for survival after included age relapse, cytogenetics, duration complete remission. Upon multivariable analysis, treatment era was an predictor survival, significant improvement overall 2008 compared prior time periods. Modern participation trials are improving relapse.